Cited 17 times in
The prognostic role of tertiary Gleason pattern 5 in a contemporary grading system for prostate cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강동혁 | - |
dc.contributor.author | 강용진 | - |
dc.contributor.author | 김명수 | - |
dc.contributor.author | 윤철용 | - |
dc.contributor.author | 정원식 | - |
dc.contributor.author | 최영득 | - |
dc.contributor.author | 함원식 | - |
dc.date.accessioned | 2017-11-02T08:35:14Z | - |
dc.date.available | 2017-11-02T08:35:14Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1365-7852 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154643 | - |
dc.description.abstract | BACKGROUND: Recently, a new prostate cancer (PC) grading system has been introduced, where Gleason score (GS) 7 (3+4) and GS 7 (4+3) are categorized into two separate groups. However, GS 7 with tertiary Gleason pattern 5 (TGP5) was not incorporated in the new grading system. In the present study, we validated the prognostic role of TGP5 in the new classification. METHODS: We retrospectively reviewed the records of 1396 patients with localized GS 6-8 PC (pT2-3N0M0) who underwent radical prostatectomy at our institution between 2005 and 2014. After excluding patients who received neoadjuvant or adjuvant therapy, or had incomplete pathological or follow-up data, 1229 patients were included in the final analysis. The Kaplan-Meier method was used to estimate and compare the probabilities of biochemical recurrence (BCR). Cox regression models were used to investigate associations between variables and the risk of BCR. RESULTS: Of 732 GS 7 patients, 75 (10.2%) had a TGP5. The BCR-free survival rate for men with TGP5 was significantly worse than for those without TGP5 (P<0.001). In multivariate Cox regression analyses for GS 7 PC, TGP5 was a significant predictor of BCR (hazard ratio 1.750, P=0.027). When the total cohort was stratified into four grade groups according to the new classification, group 2 with TGP5 had a BCR risk comparable to group 3, and group 3 with TGP5 behaved like group 4. CONCLUSIONS: Our study shows that TGP5 increased the BCR risk after RP in GS 7 PC. Moreover, we demonstrated that the presence of a TGP5 in GS 7 upgraded the BCR risk to one comparable with the next higher category under the new classification. These findings support incorporating TGP5 into GS 7 to aid with future risk assessment and follow-up scheduling for PC. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isPartOf | PROSTATE CANCER AND PROSTATIC DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Grading | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Prostatic Neoplasms/mortality* | - |
dc.subject.MESH | Prostatic Neoplasms/pathology* | - |
dc.subject.MESH | Prostatic Neoplasms/therapy | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tumor Burden | - |
dc.title | The prognostic role of tertiary Gleason pattern 5 in a contemporary grading system for prostate cancer | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Urology | - |
dc.contributor.googleauthor | W S Jang | - |
dc.contributor.googleauthor | C Y Yoon | - |
dc.contributor.googleauthor | M S Kim | - |
dc.contributor.googleauthor | D H Kang | - |
dc.contributor.googleauthor | Y J Kang | - |
dc.contributor.googleauthor | W S Jeong | - |
dc.contributor.googleauthor | M J Abalajon | - |
dc.contributor.googleauthor | W S Ham | - |
dc.contributor.googleauthor | Y D Choi | - |
dc.identifier.doi | 10.1038/pcan.2016.55 | - |
dc.contributor.localId | A04711 | - |
dc.contributor.localId | A05091 | - |
dc.contributor.localId | A04988 | - |
dc.contributor.localId | A05180 | - |
dc.contributor.localId | A04111 | - |
dc.contributor.localId | A04337 | - |
dc.contributor.localId | A04870 | - |
dc.contributor.localId | A05268 | - |
dc.relation.journalcode | J02558 | - |
dc.identifier.eissn | 1476-5608 | - |
dc.identifier.pmid | 27845330 | - |
dc.identifier.url | http://www.nature.com/pcan/journal/v20/n1/full/pcan201655a.html?foxtrotcallback=true | - |
dc.contributor.alternativeName | Kang, Dong Hyuk | - |
dc.contributor.alternativeName | Kang, Yong Jin | - |
dc.contributor.alternativeName | Kim, Myung Soo | - |
dc.contributor.alternativeName | Yoon, Cheol Yong | - |
dc.contributor.alternativeName | Jeong, Won Sik | - |
dc.contributor.alternativeName | Choi, Young Deuk | - |
dc.contributor.alternativeName | Ham, Won Sik | - |
dc.contributor.affiliatedAuthor | Kang, Yong Jin | - |
dc.contributor.affiliatedAuthor | Kim, Myung Soo | - |
dc.contributor.affiliatedAuthor | Yoon, Cheol Yong | - |
dc.contributor.affiliatedAuthor | Jeong, Won Sik | - |
dc.contributor.affiliatedAuthor | Choi, Young Deuk | - |
dc.contributor.affiliatedAuthor | Ham, Won Sik | - |
dc.contributor.affiliatedAuthor | Kang, Dong Hyuk | - |
dc.citation.title | Prostate Cancer and Prostatic Diseases | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 93 | - |
dc.citation.endPage | 98 | - |
dc.identifier.bibliographicCitation | PROSTATE CANCER AND PROSTATIC DISEASES, Vol.20(1) : 93-98, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 43701 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.